Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism
Adriana Isvoran, Maxime Louet, Diana Vladoiu, et al.
Drug Discovery Today (2016) Vol. 22, Iss. 2, pp. 366-376
Closed Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors
David Lagorce, Dominique Douguet, Maria A. Miteva, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 201
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
Ann K. Daly, Allan E. Rettie, Douglas M. Fowler, et al.
Journal of Personalized Medicine (2017) Vol. 8, Iss. 1, pp. 1-1
Open Access | Times Cited: 191
Recommendations for Clinical CYP2C9 Genotyping Allele Selection
Victoria M. Pratt, Larisa H. Cavallari, Andria L. Del Tredici, et al.
Journal of Molecular Diagnostics (2019) Vol. 21, Iss. 5, pp. 746-755
Open Access | Times Cited: 115
Genome interpretation using in silico predictors of variant impact
Panagiotis Katsonis, Kevin Wilhelm, Amanda M. Williams, et al.
Human Genetics (2022) Vol. 141, Iss. 10, pp. 1549-1577
Open Access | Times Cited: 54
Impact of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms on antiepileptic drug safety and efficacy
N. A. Galankin, Z. G. Tadtaeva, I. S. Sardaryan, et al.
Epilepsy and Paroxysmal Conditions (2025) Vol. 17, Iss. 1, pp. 70-81
Open Access | Times Cited: 1
Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy
Jarrett R. Amsden, Paul O. Gubbins
Expert Opinion on Drug Metabolism & Toxicology (2017) Vol. 13, Iss. 11, pp. 1135-1146
Closed Access | Times Cited: 50
Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9
Elodie Goldwaser, Catherine Laurent, Nathalie Lagarde, et al.
PLoS Computational Biology (2022) Vol. 18, Iss. 1, pp. e1009820-e1009820
Open Access | Times Cited: 27
Pharmacogenetics of human sulfotransferases and impact of amino acid exchange on Phase II drug metabolism
Adriana Isvoran, Yunhui Peng, Silvana Ceauranu, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 11, pp. 103349-103349
Open Access | Times Cited: 27
Recent Advances of DprE1 Inhibitors against Mycobacterium tuberculosis: Computational Analysis of Physicochemical and ADMET Properties
Patrícia S. M. Amado, Christopher M. Woodley, Maria L. S. Cristiano, et al.
ACS Omega (2022) Vol. 7, Iss. 45, pp. 40659-40681
Open Access | Times Cited: 27
Computational study of ADME-Tox prediction of selected phytochemicals from Punica granatum peels
Aneeqa Batool, Shagufta Parveen, Nusrat Shafiq, et al.
Open Chemistry (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Analysis of protein missense alterations by combining sequence‐ and structure‐based methods
Grigor V. Gyulkhandanyan, Alireza R. Rezaie, Lubka T. Roumenina, et al.
Molecular Genetics & Genomic Medicine (2020) Vol. 8, Iss. 4
Open Access | Times Cited: 39
Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
Jianxing Zhou, Zipeng Wei, Baohua Xu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
Quality by design (QbD) approach of pharmacogenomics in drug designing and formulation development for optimization of drug delivery systems
Sumeet Gupta, Vikas Jhawat
Journal of Controlled Release (2016) Vol. 245, pp. 15-26
Closed Access | Times Cited: 36
The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta‐analysis
Ying Zhang, Kelu Hou, Fang Liu, et al.
Mycoses (2021) Vol. 64, Iss. 8, pp. 860-873
Closed Access | Times Cited: 26
Mechanism of Action and Interaction of Garlic Extract and Established Therapeutics in Prostate Cancer
Marco Hoffmann, J. D. SAUER, Marius Book, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1777-1777
Open Access
Exploring the molecular structure, vibrational spectroscopic, quantum chemical calculation and molecular docking studies of curcumin: A potential PI3K/AKT uptake inhibitor
M. Govindammal, M. Prasath, Sattu Kamaraj, et al.
Heliyon (2021) Vol. 7, Iss. 4, pp. e06646-e06646
Open Access | Times Cited: 22
Mechanisms of Altered Hepatic Drug Disposition during pregnancy: small molecules
Muluneh M. Fashe, Jacqueline B. Tiley, Craig R. Lee
Expert Opinion on Drug Metabolism & Toxicology (2025)
Closed Access
Insights into molecular mechanisms of drug metabolism dysfunction of human CYP2C9*30
Maxime Louet, Céline M. Labbé, Charline Fagnen, et al.
PLoS ONE (2018) Vol. 13, Iss. 5, pp. e0197249-e0197249
Open Access | Times Cited: 27
Computational and artificial intelligence-based approaches for drug metabolism and transport prediction
Bálint Dudás, Maria A. Miteva
Trends in Pharmacological Sciences (2023) Vol. 45, Iss. 1, pp. 39-55
Closed Access | Times Cited: 8
Human Cytochrome P450 2C9 and Its Polymorphic Modifications: Electroanalysis, Catalytic Properties, and Approaches to the Regulation of Enzymatic Activity
Victoria V. Shumyantseva, Tatiana V. Bulko, Polina I. Koroleva, et al.
Processes (2022) Vol. 10, Iss. 2, pp. 383-383
Open Access | Times Cited: 12
In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases
Yagmur Tasdemiroglu, Robert G. Gourdie, Jia‐Qiang He
European Journal of Pharmacology (2022) Vol. 932, pp. 175192-175192
Open Access | Times Cited: 12
Influences of Anlotinib on Cytochrome P450 Enzymes in Rats Using a Cocktail Method
Wei Sun, Zhe Wang, Ruimin Chen, et al.
BioMed Research International (2017) Vol. 2017, pp. 1-7
Open Access | Times Cited: 21
CYP2C gene polymorphisms in North African populations
Mohsen Messaoudi, A.J. Pakstis, Sami Boussetta, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 2
Variations in the frequencies of polymorphisms in the CYP2C9 gene in six major ethnicities of Pakistan
Sagheer Ahmed, Nadeem Altaf, Mahnoor Ejaz, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 15
Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy
Baron Bechtold, John Clarke
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 17, Iss. 4, pp. 397-412
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top